Among the earliest tau-related abnormalities in AD are increases in soluble hyperphosphorylated tau (p-tau) concentrations, which can reliably be detected in cerebrospinal fluid (CSF)1 and precede the neocortical deposition of insoluble fibrillary tau pathology in AD6–8. Here, MAPT is linked to Alzheimer disease.